Trowers advises CNX Therapeutics on acquisition of Synchrony Pharma
Top 40 law firm Trowers & Hamlins has advised CNX Therapeutics Limited, a specialty pharmaceutical company with a focus on improving access to medicines that are critical to the well-being of patients on the acquisition of Synchrony Pharma Limited and its existing portfolio of commercialised products.
Founded in 2008, Synchrony focuses on the development and supply of niche injectable products, to ensure continuity of supply to customers and patients of essential medicines. The current Synchrony portfolio consists of high-quality hospital injectable products, that are used in the emergency room and to treat life-threatening conditions. Synchrony benefits from several strategic partnerships with leading manufacturers of injectable medicines in Europe and across the world.
Inflexion Private Equity, a leading mid-market private equity firm, invested in CNX Therapeutics in 2021 and is supporting the growth of the company both organically and through acquisition.
Trowers undertook legal (including intellectual property) due diligence on Synchrony Pharma, as well as advising on the acquisition documentation and the funding arrangements.
Alison Chivers, Corporate Partner at Trowers & Hamlins, commented:
"This acquisition will enable CNX Therapeutics to further establish themselves as one of the leading providers of niche speciality medicines in the UK and is an important step in the organisations growth strategy. We look forward to working with CNX Therapeutics on future projects as they grow and develop in the market."
CNX Therapeutics’ CEO, Guy Clark added:
“The addition of the Synchrony products will strengthen CNX Therapeutics’ position as an important provider of niche specialty medicines in the UK and across Europe, with the additional opportunity to expand the combined portfolio to new markets through our shared network. This acquisition is the first of many that will see CNX Therapeutics’ fulfil its ambition to grow quickly through acquisitions and achieve its goal to become a leading provider of niche and critical medicines across Europe, and also beyond. It was a pleasure to work with the Trowers team on this deal, and their sector knowledge and expertise throughout was extremely valuable.”